Evaluating the risks of public health programs: Rational antibiotic use and antimicrobial resistance
Evaluating the risks of public health programs: Rational antibiotic use and antimicrobial resistance
复制标题
DOI：
10.1111/bioe.12653
复制
发表时间：
2019-09-01
期刊：
影响因子：
2.2
通讯作者：
Buyx, Alena
中科院分区：
文献类型：
--
作者：
Rid, Annette;Littmann, Jasper;Buyx, Alena
现有的公共卫生伦理框架在如何评估公共卫生项目的风险方面没有提供足够的指导，这些项目损害了现有患者的最佳临床利益，从而造福于他人。鉴于此类项目与临床研究的相关相似性，我们建议，从临床研究中可接受风险的长期辩论中获得的见解，可以帮助提供信息并指导对损害患者最佳临床利益的公共卫生项目所构成的风险的评估。我们讨论了如何将在一种情况下学到的关于风险伦理的经验有效地转移到另一种情况下，使用所谓的“合理使用抗生素”指南的例子，该指南限制抗菌素处方，以遏制抗菌素耐药性。
Existing ethical frameworks for public health provide insufficient guidance on how to evaluate the risks of public health programs that compromise the best clinical interests of present patients for the benefit of others. Given the relevant similarity of such programs to clinical research, we suggest that insights from the long-standing debate about acceptable risk in clinical research can helpfully inform and guide the evaluation of risks posed by public health programs that compromise patients' best clinical interests. We discuss how lessons learned regarding the ethics of risk in one context can be fruitfully transferred to the other, using the example of a so-called 'rational antibiotic use' guideline that limits antimicrobial prescribing in order to curb antimicrobial resistance.